Treatment of Hepatocellular Carcinoma: Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00121914|
Recruitment Status : Unknown
Verified July 2005 by Medical University of Vienna.
Recruitment status was: Active, not recruiting
First Posted : July 21, 2005
Last Update Posted : October 18, 2005
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Hepatocellular||Procedure: percutaneous ethanol instillation (PEI)||Phase 3|
This is a randomized two-arm parallel group study.
- Study group: PEI + long-acting somatostatin
- Control group: long-acting somatostatin alone
Aims of the study:
- Does treatment with PEI+ long-acting somatostatin prolong survival as compared to treatment with long-acting somatostatin alone?
- Can time to tumour progression be extended in patients treated with PEI + long-acting somatostatin as compared to treatment with long-acting somatostatin alone?
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study With Long-Acting Somatostatin Plus Percutaneous Ethanol Instillation (PEI) Versus Long-Acting Somatostatin Alone|
|Study Start Date :||October 2000|
|Study Completion Date :||July 2005|
- survival time
- time to tumour progression
- quality of life
- causes of death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00121914
|Universitaetsklinik fuer Innere Medizin IV / Gastroenterologie und Hepatologie|
|Vienna, Austria, 1090|
|Principal Investigator:||Christian Mueller, MD||Universitaetsklinik fuer Innere Medizin IV|